IDCP guidelines: Management of HIV infection

Infectious Diseases in Clinical Practice

Volumn 6, Issue 7, 1997, Pages 422-429

  Bartlett, John G ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; DIDANOSINE; HEPATITIS B VACCINE; INDINAVIR; INFLUENZA VACCINE; ISONIAZID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PENTAMIDINE; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TUBERCULIN; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DISEASE TRANSMISSION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY TEST; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SEROLOGY; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS TRANSMISSION;

EID: 0030719548     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199706070-00003     Document Type: Review

References (13)

1. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41 (RR-17).
2. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;217: 1582.
3. Mellors J, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers in HIV-1 infection. Ann Intern Med. In press 1997.
4. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a ummary. Ann Intern Med 1996;124:349.
5. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995;21(Suppl 1).
6. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408.
7. CAESAR Coordinating Committee. Randomised trail of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413.
8. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081.
9. Culick RM, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine(3TC) [abstract Th.B.931]. In: Proceedings and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver (BC).
10. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019.
11. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276:146.
12. Lange JMA. Current problems and the future of antiretroviral drug trials. Science 1997;276:548.
13. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701.